Full View

Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

DR Spigel, M Lin, V O'Neill… - … International Journal of …, 2008 - Wiley Online Library
BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …
被引用次数：41 相关文章

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

DR Spigel, M Lin, V O'Neill, JD Hainsworth - Cancer, 2008 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib is an orally available, reversible inhibitor of epidermal growth factor
receptor (EGFR) with a proven survival advantage for patients with locally advanced or …

[引用][C] Final Survival and Safety Results From a Multicenter, Open-label, Phase 3b Trial of Erlotinib in Patients With Advanced Nonsmall Cell Lung Cancer

DR SPIGEL, M LIN, V O'NEILL, JD HAINSWORTH - Cancer, 2008 - pascal-francis.inist.fr
Final Survival and Safety Results From a Multicenter, Open-label, Phase 3b Trial of Erlotinib
in Patients With Advanced Nonsmall Cell Lung Cancer CNRS Inist Pascal-Francis CNRS …

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.

DR Spigel, M Lin, V O'Neill, JD Hainsworth - Cancer, 2008 - europepmc.org
Background Erlotinib is an orally available, reversible inhibitor of epidermal growth factor
receptor (EGFR) with a proven survival advantage for patients with locally advanced or …

[引用][C] Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

DR Spigel, M Lin, V O'Neill, JD Hainsworth - Cancer, 2008 - cir.nii.ac.jp
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in
patients with advanced nonsmall cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術 …

[引用][C] Final Survival and Safety Results From a Multicenter, Open-label, Phase 3b Trial of Erlotinib in Patients With Advanced Nonsmall Cell Lung Cancer

DR SPIGEL, LIN MING, V O'NEILL, JD HAINSWORTH - Cancer, 2008 - Wiley-Blackwell